Some patients who have a rare metabolic disease have access to a new medication that treats the complications of lipodystrophy.
Food and Drug Administration approved the injection metreleptin, which is marketed as Myalept, as a replacement therapy to treat the conditions of leptin deficiency in patients who have lipodystrophy. Patients who have congenital generalized lipodystrophy are born with little or no fat tissue, while patients who have acquired generalized lipodystrophy lose fat tissue over time.
The medication isn’t recommended for obese patients and isn’t approved for use in patients who have HIV-related lipodystrophy or in patients who have metabolic disease that isn’t associated with lipodystrophy.
The medication is available only through the Myalept risk evaluation and mitigation strategy program. Prescribers and pharmacies must be certified with the program to dispense the medication.